Elite Pharmaceuticals, Inc. specializes in the development of oral controlled release products, such as delayed, sustained, targeted and pulsatile release tables, pellets, capsules, granules and powders.  The Company’s primary focus is in the therapeutic areas of pain management, allergy, cardiovascular and infection.

 Recent Press Releases:

1/26/2012	ELITE PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF SUPPLEMENTAL APPLICATION FOR HYDROMORPHONE
1/3/2012	ELITE PHARMACEUTICALS SECURES $5 MILLION FUNDING COMMITMENT
10/19/2011	ELITE PHARMACEUTICALS ANNOUNCES RESULTS OF ANNUAL MEETING OF STOCKHOLDERS
9/27/2011	ELITE PHARMACEUTICALS AND ECR PHARMACEUTICALS LAUNCH LODRANE D® ALLERGY PRODUCT
8/16/2011	Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter Ended June 30, 2011 Revenues up 19% - Positive Operating Cash Flow – Phentermine Launched